According to Intellia Therapeutics's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.11. At the end of 2024 the company had a P/S ratio of 49.5.
Year | P/S ratio | Change |
---|---|---|
2024 | 49.5 | -34.23% |
2023 | 75.3 | 30.42% |
2022 | 57.7 | -78.32% |
2021 | 266 | 339.37% |
2020 | 60.6 | 254.65% |
2019 | 17.1 | -15.77% |
2018 | 20.3 | -34.9% |
2017 | 31.2 | 8.8% |
2016 | 28.6 |